Preeradication vaccine policy options for poliovirus infection and disease control

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 516-543

  Thompson, Kimberly M ^a,b   Pallansch, Mark A ^c   Duintjer Tebbens, Radboud J ^a   Wassilak, Steve G ^c   Kim, Jong Hoon ^a   Cochi, Stephen L ^c  

^a Kid Risk Inc   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Policy options; Poliovirus; Vaccination

Indexed keywords

CURRENT PRACTICES; LOW PRIORITIES; POLICY ANALYSIS; POLICY OPTIONS; POLIOVIRUS; PRODUCT CHOICE; SOURCES OF VARIABILITY; VACCINATION;

DECISION TREES; UNCERTAINTY ANALYSIS;

VACCINES;

POLIOMYELITIS VACCINE;

DISEASE CONTROL; DISEASE TRANSMISSION; HEALTH POLICY; HEALTH WORKER; LITERATURE REVIEW; POLICY ANALYSIS; POLICY MAKING; POLIOMYELITIS; REINTRODUCTION; RISK ASSESSMENT; VACCINE; VIRUS;

ARTICLE; HEALTH CARE POLICY; HUMAN; POLIOMYELITIS;

HEALTH POLICY; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINES;

POLIOVIRUS;

EID: 84875928962     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12019     Document Type: Article

References (112)

1. Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. Risk Analysis, 2013; 33(4):505-515.
2. World Health Organization. Transmission of wild poliovirus type 2: Apparent global interruption. Weekly Epidemiological Record, 2001; 76:95-97.
3. World Health Organization. Global Polio Eradication Initiative-Cases of wild poliovirus by country and by year 2000-2012. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx, Accessed January 2, 2013.
4. World Health Organization. Polio news-April 2001. Geneva; 2001. Report No.: WHO/POLIO/01.02.
5. World Health Organization. Polio news-December 2000. Geneva; 2000. Report No.: WHO/POLIO/00.08.
6. World Health Organization. India records one year without polio cases. Available at: http://www.who.int/mediacentre/news/releases/2012/polio_20120113/en/index.html, Accessed January 2, 2013.
7. World Health Organization Regional Office for Europe. WHO epidemiological brief: Tajikistan polio outbreak and regional response 2010. Available at: http://www.euro.who.int/_data/assets/pdf_file/0019/118342/EPI_TJK_Issue3.pdf, Accessed January 2, 2013.
8. MacDonald N, Hébert PC. Polio outbreak in Tajikistan is cause for alarm. Canadian Medical Association Journal, 2010; 182(10):1013.
9. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 2013; 33(4):647-663.
10. World Health Organization. Circulating vaccine-derived poliovirus (cVDPV) 2000-2012. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx, Accessed January 2, 2013.
11. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste S, Diop O, Wassilak SGF, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses. Risk Analysis, 2013; 33(4):680-702.
12. Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch MA, Kew OM. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. Journal of Infectious Diseases, 2011; 203(7):898-909.
13. World Health Assembly. Poliomyelitis: Mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization, 2008. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf, Accessed January 2, 2013.
14. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
15. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape Journal of Medicine, 2008; 10(8):190.
16. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines, 2012; 11(4):449-459.
17. Thompson KM, Duintjer Tebbens RJ. Challenges related to the economic evaluation of the direct and indirect benefits and the costs of disease elimination and eradication efforts. Chapter 9 in Cochi SL, Dowdle WR (eds). Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: MIT Press, 2011.
18. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 2006; 26(6):1423-1440.
19. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the Global Polio Eradication Initiative. Vaccine, 2011; 29(2):334-343.
20. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
21. Sangrujee NK, Duintjer Tebbens RJ, Cáceres VM, Thompson KM. Policy decision options during the first five years following certification of polio eradication. Medscape General Medicine, 2003(December 19); 5(4):35.
22. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
23. Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. Risk Analysis, 2006; 26(6):1419-1421.
24. Aylward RB, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann DL. Risk management in a polio-free world. Risk Analysis, 2006; 26(6):1441-1448.
25. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
26. Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of polio risk management policies after eradication. Risk Analysis, 2006; 26(6):1507-1531.
27. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 2006; 26(6):1541-1556.
28. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: Insights and lessons learned through modeling. Risk Analysis, 2006; 26(6):1571-1580.
29. de Gourville EM, Sangrujee N, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Global surveillance and the value of information: The case of the global polio laboratory network. Risk Analysis, 2006; 26(6):1557-1569.
30. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis, 2008; 28(4):855-876.
31. Duintjer Tebbens RJ, Pallansch MA, Alexander JP, Jr., Thompson KM. Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine, 2010; 28(26):4312-4327.
32. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Weekly Epidemiological Record, 2010; 85:213-228.
33. World Health Organization. WHO vaccine-preventable diseases: Monitoring system-2012 global summary (data up to December 2012)2012. Available at: http://apps.who.int/immunization_monitoring/en/globals-ummary/ScheduleResult.cfm, Accessed January 2, 2013.
34. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
35. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 2013; 33(4):703-749.
36. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. Pp. 605-630 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines, 5th ed. Saunders Elsevier, 2008.
37. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 1991; 13:926-939.
38. Sutter RW, Cáceres VM, Más Lago P. The role of routine immunization in the post-certification era. Bulletin of the World Health Organization, 2004; 82(1):31-38.
39. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases, 2001; 33(4):531-541.
40. Kavanagh B. The GRADE system for rating clinical guidelines. PLoS Medicine, 2009; 6(9):e1000094.
41. GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal, 2004; 328:1-8.
42. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. American Journal of Epidemiology, 1988; 128(3):615-628.
43. Nirmal S, Cherian T, Samuel B, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine, 1998; 16(9-10):928-931.
44. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemani N, Galindo B, Burton A, Friede M, Landaverde M, Sutter RW. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. Journal of Infectious Diseases, 2011; 201(9):1344-1352.
45. Mohammed AJ, Al Awaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, Burton A, Sreevatsava M, Sutter RW. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine, 2010; 362(25):2351-2359.
46. Wood DJ, Heath AB. Comparability of poliovirus neutralizing antibody tests. Biologicals, 1992; 20(4):293-300.
47. World Health Organization. Polio laboratory manual. Geneva; 2004 November. Report No.: WHO/IVB/04.10.
48. Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PH, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. Polio outbreaks and poliovirus vaccine availability for response. Public Health Reports, 2012; 127(1):23-37.
49. Bhaskaram P, Nair KM, Hemalatha P, Murthy N, Nair P. Systemic and mucosal immune response to polio vaccination with additional dose in newborn period. Journal of Tropical Pediatrics, 1997; 43:232-234.
50. World Health Organization Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Bulletin of the World Health Organization, 1996; 74(3):253-268.
51. Sormunen H, Stenvik M, Eskola J, Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. Journal of Medical Virology, 2001; 63(4):305-310.
52. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with vero-produced enhanced potency inactivated poliovirus vaccine. Pediatric Infectious Disease Journal, 1997; 16(3):312-322.
53. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. Morbidity and Mortality Weekly Report, 2009; 58(30):829-830.
54. Fine PEM, Sutter RW, Orenstein WA. Stopping a polio outbreak in the post-eradication era. Developments in Biologicals, 2001; 105:129-147.
55. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine, 2007; 356(15):1536-1544.
56. Myaux JA, Unicomb L, Besser RE, Modlin JF, Uzma A, Islam AM, Santosham M. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatric Infectious Disease Journal, 1996; 15(3):204-209.
57. Weckx LY, Schmidt BJ, Herrmann AA, Miyasaki CH, Novo NF. Early immunization of neonates with trivalent oral poliovirus vaccine. Bulletin of the World Health Organization, 1992; 70(1):85-91.
58. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: A prospective evaluation in Brazil and the Gambia. World Health Organization collaborative study group on oral poliovirus vaccine. Journal of Infectious Diseases, 1995; 171(5):1097-1106.
59. El-Sayed N, El-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HG, Burton AH, Sreevatsava M, Malankar P, Wahdan MH, Sutter RW. Monovalent type 1 oral poliovirus vaccine in newborns. New England Journal of Medicine, 2008; 359(16):1655-1665.
60. Böttiger M, Litvinov S, Assaad F, Lundbeck H, Heller L, Beausoleil E. Antibodies against poliomyelitis and measles viruses in immunized and unimmunized children, Ghana 1976-78. Bulletin of the World Health Organization, 1981; 59(5):729-736.
61. Osei-Kwasi M, Afari EA, Mimura K, Obeng-Ansah I, Ampofo WK, Nkrumah FK. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. Bulletin of the World Health Organizaton, 1995; 73(1):41-46.
62. Khare S, Kumari S, Nagpal I, Sharma D, Verghese T. Oral polio vaccination in infants: Beneficial effect of additional dose at birth. Indian Journal of Pediatrics, 1993; 60(2):275-281.
63. Jain P, Dutta A, Nangia S, Khare S, Saili A. Seroconversion following killed polio vaccine in neonates. Indian Journal of Pediatrics, 1997; 64(4):511-515.
64. Bhaskaram P, Balakrishna N. Effect of administration of 200, 000 IU of vitamin A to women within 24 hrs after delivery on response to PPV administered to the newborn. Indian Pediatrics, 1998; 35(3):217-222.
65. John TJ, Jain H, Ravishankar K, Amaresh A, Verma H, Deshpande J, Pallansch MA, Singh AP, Sreevatsava M, Burton A, Malankar P, Chatterjee A, Sutter RW. Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials. Vaccine, 2011; 29(34):5793-5801.
66. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande JM, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial. Lancet, 2010; 376(9753):1682-1688.
67. Maldonado YA, Peña-Cruz V, Sanchez MD, Logan L, Blandón S, Cantwell MF, Matsui SM, MillanVelasco F, Valdespino JL, Sepulveda J. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. Journal of Infectious Diseases, 1997; 175(3):545-553.
68. Waggie Z, Geldenhuys H, Sutter RW, Jacks M, Mulenga H, Mahomed H, De Kock M, Hanekom W, Pallansch MA, Kahn AL, Burton AH, Sreevatsava M, Hussey G. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. Journal of Infectious Diseases, 2012; 205(2):228-236.
69. Simasathien S, Migasena S, Beuvery C, Vansteenis G, Samakoses R, Pitisuttitham P, Vesikari T. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scandinavian Journal of Infectious Diseases, 1994; 26(6):731-738.
70. Triki H, Abdallah M, Ben Aissa R, Bouratbine A, Kacem MBA, Bouraoui S, Koubaa C, Zouari S, Mohsni E, Crainic R, Dellagi K. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine, 1997; 15(10):1123-1129.
71. Dong DX, Hu XM, Liu WJ, Li JS, Jin YC, Tan SG, Chen TQ, Fu JZ, Niu BY, Yu HM, Zhou Y. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bulletin of the World Health Organization, 1986; 64(6):853-860.
72. Vodopija I, Baklaic Z, Vlatkovic R, Bogaerts H, Delem A, Andre FE. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. Vaccine, 1986; 4(4):233-236.
73. Giammanco G, De Grandi V, Lupo L, Mistretta A, Pignato S, Teuween D, Bogaerts H, Andre FE. Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine. European Journal of Epidemiology, 1988; 4(1):121-123.
74. Cohen-Abbo A, Culley BS, Reed GW, Sannella EC, Mace RL, Robertson SE, Wright PF. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatric Infectious Diseases Journal, 1995; 14(2):100-106.
75. Osei-Kwasi M, Afari EA, Mimura K, Obengansah I, Ampofo WK, Nkrumah FK. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. Bulletin of the World Health Organization, 1995; 73(1):41-46.
76. Hardas U, Pathak A, Jahagirdar V. Sero-conversion after oral polio vaccine. Indian Journal of Pediatrics, 1978; 45(10):310-313.
77. John T. Immune response of neonates to oral poliomyelitis vaccine. British Medical Journal, 1984; 289(6449):881.
78. Agarwal A, Sharma D, Kumari S, Khare S. Antibody response to three doses of standard and double dose of trivalent oral polio vaccine. Indian Pediatrics, 1991; 28(10):1141-1145.
79. Bavdekar SB, Naik S, Nadkarni SS, Kamat JR, Deshpande JM, Vaswani LK. Effect of passively transferred anti-poliovirus antibodies on seroconversion. Indian Journal of Pediatrics, 1999; 66(1):45-48.
80. Semba RD, Muhilal, Mohgaddam NE, Munasir Z, Akib A, Permaesih D, Muherdiyantiningsih, Osterhaus A. Integration of vitamin A supplementation with the expanded program on immunization does not affect seroconversion to oral poliovirus vaccine in infants. Journal of Nutrition, 1999; 129(12):2203-2205.
81. Taffs RE, Enterline JC, Rusmil K, Muhilal, Suwardi SS, Rustama D, Djatnika, Cobra C, Semba RD, Cohen N, Asher DM. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine. Bulletin of the World Health Organization, 1999; 77(6):484-491.
82. Lahrech MT, Caudrelier P. Immunological response of Moroccan children and newborns to oral poliovirus vaccine prepared on vero cells. Vaccine, 1990; 8(4):306-307.
83. Oduntan S, Lucas A, Wennen E. The immunological response of Nigerian infants to attenuated and inactivated poliovaccines. Annals of Tropical Medicine and Parasitology, 1978; 72(2):111-115.
84. Forbes C, Fernando N, de la Motte P, Mendis N. A survey to determine the immunity status and antibody creating effect of oral polio vaccine. Journal of Tropical Medicine and Hygiene, 1980; 83(3):109-113.
85. Hogg K, Hogg G. The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a combination pentavalent vaccine. Vaccine, 2003; 21(21-22):2906-2910.
86. Prikazsky V, Leroux-Roels G, Van Damme P, Safary A, Colau B, Duchene M. Comparative pre-clinical and clinical experience with oral polio vaccine produced on mrc-5 cells or on primary monkey kidney cells. Vaccine, 2005; 23(33):4219-4227.
87. Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. Journal of Infectious Diseases, 2012; 205(2):237-243.
88. Lee CY, Thipphawong J, Huang LM, Lee PI, Chiu HH, Lin W, Debois H, Harrison D, Xie F, Barreto L. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics, 1999; 103(1):25-30.
89. Parent du Châtelet I, Merchant AT, Fisher-Hoch S, Luby SP, Plotkin SA, Moatter T, Agboatwalla M, McCormick JB. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine, 2003; 21(15):1710-1718.
90. Heymann DL, Murphy K, Brigaud M, Aymard M, Tembon A, Maben GK. Oral poliovirus vaccine in tropical Africa: Greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. Bulletin of the World Health Organization, 1987; 65(4):495-501.
91. Richardson G, Linkins RW, Eames MA, Wood DJ, Campbell PJ, Ankers E, Deniel M, Kabbaj A, Magrath DI, Minor PD, Patriarca PA. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bulletin of the World Health Organization, 1995; 73(6):769-777.
92. Rümke HC, Schlumberger M, Floury B, Nagel J, van Steenis B. Serological evaluation of a simplified immunization schedule using quadruple DPT-polio vaccine in Burkina Faso. Vaccine, 1993; 11(11):1113-1118.
93. Sutter RW, Cochi SL, Melnick JL. Live attenuated poliovirus vaccines. In Plotkin SA, Orenstein WA (eds). Vaccines, 3rd ed. Philadelphia: W.B. Saunders, 1999.
94. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 2013; 33(4):606-646.
95. Böttiger M. Polio immunity to killed vaccine: An 18-year follow-up. Vaccine, 1990; 8(5):443-445.
96. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. Journal of Infectious Diseases, 1993; 168(2):452-454.
97. Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. Vaccine, 2009; 27(20):2689-2694.
98. Simoes EAF, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response to two doses of inactivated poliovirus vaccine of enhanced potency. American Journal of Diseases of Children, 1985; 139:977-980.
99. Singh J, Ravi RN, Dutta AK, Kumari S, Khare S. Immunogenicity of enhanced potency inactivated polio vaccine. Indian Pediatrics, 1992; 29(11):1353-1356.
100. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases, 2012; 16(2):e110-e116.
101. Dayan GH, Thorley M, Yamamura Y, Rodriguez N, McLaughlin S, Torres LM, Seda A, Carbia M, Alexander LN, Caceres V, Pallansch MA. Serologic response to inactivated poliovirus vaccine: A randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. Journal of Infectious Diseases, 2007; 195(1):12-20.
102. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. Journal of the American Medical Association, 2004; 292(14):1696-1701.
103. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases, 1991; 163:1-6.
104. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines, 5th ed. Philadelphia: Saunders Elsevier, 2008.
105. World Health Organization. Report of the seventh meeting of the Global Technical Consultative Group for poliomyelitis eradication. Geneva: Department of Vaccines and Biologicals, World Health Organization, 2002 April 9-11. Report No.: WHO/V&B/02.12.
106. Herremans TMPT, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. Journal of Immunology, 1999; 162:5011-5018.
107. Estivariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, Awale J, Burton A, Bahl S, Chatterjee A, Aylward RB. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: A community-based, randomised controlled trial. Lancet Infectious Diseases, 2012; 12(2):128-135.
108. Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Human Vaccines and Immunotherapeutics, 2012; 8(3):347-354
109. Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB. Asymptomatic wild-type poliovirus infection among children with previous oral poliovirus vaccination. Journal of Infectious Diseases, 2010; 10:1535-1543.
110. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-India, January 2007-May 2009. Morbidity and Mortality Weekly Report, 2010; 58(26):718-723.
111. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2009-June 2010. Morbidity and Mortality Weekly Report, 2010; 59(26):802-807.
112. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC. Implications of a circulating vaccine-derived poliovirus in Nigeria. New England Journal of Medicine, 2010; 326(25):2360-2369.